Analysts Set Theravance Biopharma, Inc. (NASDAQ:TBPH) PT at $21.83

Shares of Theravance Biopharma, Inc. (NASDAQ:TBPH) have earned a consensus recommendation of “Moderate Buy” from the eight analysts that are covering the stock, Marketbeat reports. Four analysts have rated the stock with a hold rating, two have issued a buy rating and two have given a strong buy rating to the company. The average 1-year price target among analysts that have updated their coverage on the stock in the last year is $21.8333.

Several equities analysts have recently commented on the stock. TD Cowen boosted their target price on shares of Theravance Biopharma from $13.00 to $15.00 and gave the stock a “hold” rating in a report on Monday, March 23rd. BTIG Research reissued a “buy” rating and issued a $21.00 target price on shares of Theravance Biopharma in a report on Friday, March 20th. B. Riley Financial boosted their target price on shares of Theravance Biopharma from $14.00 to $17.00 and gave the stock a “neutral” rating in a report on Tuesday, April 7th. Zacks Research raised shares of Theravance Biopharma from a “hold” rating to a “strong-buy” rating in a report on Thursday, March 19th. Finally, Wall Street Zen downgraded shares of Theravance Biopharma from a “buy” rating to a “hold” rating in a report on Saturday, May 16th.

Theravance Biopharma Price Performance

TBPH opened at $16.41 on Wednesday. The firm has a market cap of $845.98 million, a P/E ratio of 7.46 and a beta of 0.19. Theravance Biopharma has a 1-year low of $9.10 and a 1-year high of $21.03. The company has a 50 day simple moving average of $16.10 and a two-hundred day simple moving average of $17.56.

Theravance Biopharma (NASDAQ:TBPH) last released its earnings results on Tuesday, March 31st. The biopharmaceutical company reported ($0.10) EPS for the quarter. Theravance Biopharma had a return on equity of 18.84% and a net margin of 104.34%.The company had revenue of $17.70 million during the quarter. Equities analysts anticipate that Theravance Biopharma will post 0.95 earnings per share for the current year.

Insider Activity at Theravance Biopharma

In other news, SVP Rhonda Farnum sold 31,067 shares of the business’s stock in a transaction on Monday, March 16th. The shares were sold at an average price of $13.96, for a total value of $433,695.32. Following the transaction, the senior vice president owned 232,699 shares of the company’s stock, valued at approximately $3,248,478.04. The trade was a 11.78% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Company insiders own 7.65% of the company’s stock.

Institutional Investors Weigh In On Theravance Biopharma

A number of hedge funds have recently bought and sold shares of the business. Bank of America Corp DE raised its stake in Theravance Biopharma by 78.2% during the first quarter. Bank of America Corp DE now owns 189,155 shares of the biopharmaceutical company’s stock valued at $3,070,000 after purchasing an additional 82,978 shares in the last quarter. California State Teachers Retirement System raised its stake in Theravance Biopharma by 1,649.4% during the first quarter. California State Teachers Retirement System now owns 40,761 shares of the biopharmaceutical company’s stock valued at $662,000 after purchasing an additional 38,431 shares in the last quarter. Empowered Funds LLC purchased a new stake in Theravance Biopharma during the first quarter valued at $900,000. Quantinno Capital Management LP raised its stake in Theravance Biopharma by 32.9% during the first quarter. Quantinno Capital Management LP now owns 18,038 shares of the biopharmaceutical company’s stock valued at $293,000 after purchasing an additional 4,463 shares in the last quarter. Finally, Rangeley Capital LLC purchased a new stake in Theravance Biopharma during the first quarter valued at $1,672,000. Hedge funds and other institutional investors own 99.10% of the company’s stock.

About Theravance Biopharma

Theravance Biopharma is a biopharmaceutical company focused on the discovery, development and commercialization of innovative medicines, primarily in the areas of respiratory disease, inflammatory and immunology, and rare disorders. The company develops small-molecule therapies designed to address unmet medical needs by targeting specific molecular pathways. Its lead marketed product, YUPELRI® (revefenacin) inhalation solution, is the first and only once-daily, long-acting muscarinic antagonist (LAMA) approved by the U.S.